Biomarin Pharmaceutical (BSP:B1MR34) YoY EPS Growth : 62.87% (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Biomarin Pharmaceutical YoY EPS Growth?

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months. Biomarin Pharmaceutical's YoY EPS Growth for the quarter that ended in Mar. 2024 was 62.87%.

Biomarin Pharmaceutical's Earnings per Share (Diluted) for the three months ended in Mar. 2024 was R$1.15.

Biomarin Pharmaceutical YoY EPS Growth Historical Data

The historical data trend for Biomarin Pharmaceutical's YoY EPS Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biomarin Pharmaceutical YoY EPS Growth Chart

Biomarin Pharmaceutical Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

YoY EPS Growth

Get a 7-Day Free Trial

68.74

4,435.58

-108.55

298.69

8.34

Biomarin Pharmaceutical Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
YoY EPS Growth	Get a 7-Day Free Trial															-55.17	85.75	594.29	6,825.00	62.87

Biomarin Pharmaceutical YoY EPS Growth Calculation

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months.

Biomarin Pharmaceutical's YoY EPS Growth for the fiscal year that ended in Dec. 2023 is calculated as:

	YoY EPS Growth (A: Dec. 2023 )
=	(Earnings per Share (Diluted) (A: Dec. 2023 )	-	Earnings per Share (Diluted) (A: Dec. 2022 ))	/	\| Earnings per Share (Diluted) (A: Dec. 2022 ) \|
=	(2.131	-	1.967)	/	\| 1.967 \|
=	8.34 %

Biomarin Pharmaceutical's YoY EPS Growth for the quarter that ended in Mar. 2024 is calculated as:

	YoY EPS Growth (Q: Mar. 2024 )
=	(Earnings per Share (Diluted) (Q: Mar. 2024 )	-	Earnings per Share (Diluted) (Q: Mar. 2023 ))	/	\| Earnings per Share (Diluted) (Q: Mar. 2023 )) \|
=	(1.145	-	0.703)	/	\| 0.703 \|
=	62.87 %

Biomarin Pharmaceutical YoY EPS Growth Related Terms

Thank you for viewing the detailed overview of Biomarin Pharmaceutical's YoY EPS Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Biomarin Pharmaceutical (BSP:B1MR34) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biomarin Pharmaceutical Inc (BSP:B1MR34) » Definitions » YoY EPS Growth

Comparable Companies

Traded in Other Exchanges

BMRN:USA 1BMRN:Italy BM8:Germany

Address

770 Lindaro Street, San Rafael, CA, USA, 94901

Website

http://www.bmrn.com

BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU (in addition to long-standing U.S. rights, BioMarin has reacquired international rights for Kuvan and Palynziq from Merck KGaA). Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) was approved in Europe in 2022 and in the U.S. in 2023.

Biomarin Pharmaceutical (BSP:B1MR34) Headlines

No Headlines